A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
|
|
- Janel Rich
- 5 years ago
- Views:
Transcription
1 A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients Viktor Grünwald, 1 David McDermott, 2 Michael Atkins, 3 Robert Motzer, 4 Brian Rini, 5 Bernard Escudier, 6 Lawrence Fong, 7 Richard W. Joseph, 8 Sumanta Pal, 9 Mario Sznol, 10 John Hainsworth, 11 Walter M. Stadler, 12 Thomas Hutson, 13 Alain Ravaud, 14 Sergio Bracarda, 15 Cristina Suarez, 16 Toni Choueiri, 17 YounJeong Choi, 18 Mahrukh A. Huseni, 18 Gregg D. Fine, 18 Thomas Powles 19 1 Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Centre for Internal Medicine, Hannover Medical School, Germany; 2 Beth Israel Deaconess Medical Center, Boston, MA; 3 Georgetown Lombardi Comprehensive Cancer Center, Washington, DC; 4 Memorial Sloan Kettering Cancer Center, New York, NY; 5 Cleveland Clinic, Cleveland, OH; 6 Gustave Roussy, Villejuif, France; 7 University of California, San Francisco School of Medicine, San Francisco, CA; 8 Mayo Clinic Hospital Florida, Jacksonville, FL; 9 City of Hope Comprehensive Cancer Center, Duarte, CA; 10 Yale School Of Medicine, New Haven, CT; 11 Sarah Cannon Research Institute, Nashville, TN; 12 University of Chicago Medicine, Chicago, IL; 13 Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX; 14 CHU Hopitaux de Bordeaux - Hôpital Saint-André, Bordeaux, France; 15 Ospedale San Donato, Arezzo, Italy; 16 Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 17 Dana-Farber Cancer Institute, Boston, MA; 18 Genentech, Inc., South San Francisco, CA, USA; 19 Barts Cancer Institute, Queen Mary University of London, London, UK Presented at the Annual Meeting of the German, Austrian and Swiss Associations for Haematology and Medical Oncology, 01-Oct-2017, Stuttgart, Germany.
2 Disclosure of conflicts of interest 1. Appointment Medical School Hannover 2. Consultant BMS, MSD, Merck Kga, AZ, Eisai, Ipsen, Lilly, Pfizer, Ipsen, Eisai 3. Stocks none 4. Patent none 5. Honoraria Astra Zeneca, BMS, MSD, Merck Serono, Ipsen, Eisai, Novartis, EUSAPharm 6. Financial research support Pfizer (Wyeth), BMS, MSD, Novartis, AZ 7. Other financial support MSD, BMS
3 Cancer Immunity Cycle IL-2 Priming and activation Cancer antigen presentation Release of cancer cell antigens Trafficking of T cells to tumors Infiltration of T cells into tumors Recognition of cancer cells by T cells Killing of cancer cells Atezolizumab 1,2 Bevacizumab Immune therapy (high dose IL-2) is associated with long-term durable responses in patients with mrcc 3 Atezolizumab (anti PD-L1) monotherapy has demonstrated anti-tumor activity and tolerable safety in mrcc 1,4 Bevacizumab (VEGF inhibitor) + IFN-α-2a is approved for use in first-line mrcc 1. Herbst Nature Chen Immunity Yan JCO McDermott JCO IL-2, interleukin-2. mrcc, metastatic renal cell carcinoma. Figure adapted from Chen Immunity 2013.
4 CD8 IHC Atezolizumab + Bevacizumab A Phase Ib study in first-line mrcc showed anti-tumor activity and a tolerable safety profile for atezolizumab + bevacizumab 1,2 Sequential tumor biopsies provided preliminary evidence of enhanced anti-tumor immune responses following treatment with bevacizumab and atezolizumab + bevacizumab 2 Pre-treatment Post bevacizumab Post atezolizumab + bevacizumab 1. Sznol, ASCO GU, Wallin, Nat Commun, Figures reprinted from Wallin JJ, et al. Nat Commun. 2016;7: The Authors 2016; licensed under a Creative Commons Attribution 4.0 International License.
5 IMmotion150 (Phase II) Trial Design Treatment naive, locally advanced or metastatic RCC N = 305 Stratification: Prior nephrectomy PD-L1 IHC expression ( 5% IC level) MSKCC risk category R 1:1:1 First-line treatment Atezolizumab 1200 mg IV + bevacizumab 15 mg/kg q3w Atezolizumab 1200 mg IV q3w Sunitinib 50 mg (4 wk on, 2 wk off) PD Crossover treatment permitted a Atezolizumab + bevacizumab Atezolizumab + bevacizumab The coprimary endpoints are PFS (RECIST v1.1 by IRF) in ITT and PD-L1+ patients IMmotion150 was designed to be hypothesis generating and inform the trial design of the Phase III study IMmotion151 Amendments included: Based on Phase 1a data, the definition of PD-L1 positivity was revised from 5% to 1% of IC expressing PD-L1 1 In addition to ITT patients, PD-L1+ patients were included in the coprimary endpoint of IRF-assessed PFS, after interim analyses IC, tumor-infiltrating immune cells; IRF, independent review facility. 1. McDermott JCO a Crossover from atezolizumab monotherapy not allowed in Europe.
6 Baseline Demographics (ITT) Sunitinib n = 101 Atezolizumab + bevacizumab n = 101 Atezolizumab n = 103 Age, median (range), y 61 (25-85) 62 (32-88) 61 (27-81) Male, n (%) 79 (78%) 74 (73%) 77 (75%) KPS 80, n (%) 94 (93%) 99 (99%) 101 (99%) Predominant clear cell histology, n (%) 96 (96%) 97 (96%) 95 (92%) Sarcomatoid component, n (%) 14 (14%) 15 (15%) 16 (15%) Prior nephrectomy, n (%) 88 (87%) 88 (87%) 89 (86%) MSKCC risk category, n (%) Favorable (0) 21 (21%) 30 (30%) 26 (25%) Intermediate (1 or 2) 70 (69%) 62 (61%) 69 (67%) Poor ( 3) 10 (10%) 9 (9%) 8 (8%) 1% of IC expressing PD-L1 (PD-L1+), n (%) 60 (59%) 50 (50%) 54 (52%) Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo.
7 IRF-Assessed PFS ITT Atezolizumab + bevacizumab Atezolizumab Sunitinib Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 1.00 (0.69, 1.45) 1.19 (0.82, 1.71) P Value a Atezo, atezolizumab; Bev, bevacizumab. a P values are for descriptive purposes only and not adjusted for multiple comparisons.
8 IRF-Assessed PFS ITT Atezolizumab + bevacizumab Atezolizumab Sunitinib Atezo: 6.1 mo (5.4, 13.6) Sunitinib: 8.4 mo (7.0, 14.0) Atezo + bev: 11.7 mo (8.4, 17.3) Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 1.00 (0.69, 1.45) 1.19 (0.82, 1.71) P Value a a P values are for descriptive purposes only and not adjusted for multiple comparisons.
9 IRF-Assessed PFS 1% of IC Expressing PD-L1 Atezolizumab + bevacizumab Atezolizumab Sunitinib Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 0.64 (0.38, 1.08) 1.03 (0.63, 1.67) P Value a a P values are for descriptive purposes only and not adjusted for multiple comparisons.
10 IRF-Assessed PFS 1% of IC Expressing PD-L1 Atezolizumab + bevacizumab Atezolizumab Sunitinib Atezo: 5.5 mo (3.0, 13.9) Sunitinib: 7.8 mo (3.8, 10.8) Atezo + bev: 14.7 mo (8.2, 25.1) Atezo + bev vs sunitinib Atezo vs sunitinib Stratified HR (95% CI) 0.64 (0.38, 1.08) 1.03 (0.63, 1.67) P Value a a P values are for descriptive purposes only and not adjusted for multiple comparisons.
11 IRF-Assessed PFS in Key Subgroups Atezolizumab + Bevacizumab vs Sunitinib Sarcomatoid Liver metastasis MSKCC risk IC expressing PD-L1 Baseline Factor Yes No Yes No Favorable Intermediate Poor < 1% 1% and < 5% 5% and < 10% 10% All patients (ITT) n Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. In favor of atezo + bev In favor of sunitinib 1 Hazard Ratio
12 IRF-Assessed PFS in Key Subgroups Atezolizumab vs Sunitinib Sarcomatoid Liver metastasis MSKCC risk IC expressing PD-L1 Baseline Factor Yes No Yes No Favorable Intermediate Poor < 1% 1% and < 5% 5% and < 10% 10% All patients (ITT) n Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. Hazard Ratio In favor of atezo In favor of sunitinib 3.5
13 Confirmed IRF-Assessed ORR ITT 1% of IC expressing PD-L1 46% 29% 32% 25% 27% 28% PR 5% 7% 11% 7% 12% 15% CR 75% of responses are ongoing across treatment arms, and the median DOR is not estimable due to an insufficient number of PFS events in responders Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo.
14 Safety Summary n (%) Sunitinib n = 100 Median treatment duration (range), mo 6.7 ( ) Atezolizumab + Bevacizumab n = 101 Atezo: 11.8 ( ) Bev: 10.3 ( ) Atezolizumab n = ( ) All-Grade AEs, any cause 99 (99%) 101 (100%) 101 (98%) Treatment-related AE 96 (96%) 91 (90%) 86 (83%) Grade 3-4 AEs, any cause 69 (69%) 64 (63%) 41 (40%) Treatment-related Grade 3-4 AEs 57 (57%) 40 (40%) 17 (17%) AEs leading to death a 2 (2%) 3 (3%) 2 (2%) Treatment-related AEs leading to death a 2 (2%) 1 (1%) 0 AEs leading to withdrawal from treatment 10 (10%) 15 (15%) 7 (7%) Treatment-related AEs leading to withdrawal from treatment 9 (9%) 9 (9%) 3 (3%) AEs leading to dose modification or interruption 70 (70%) 61 (60%) 28 (27%) a Sunitinib arm: sudden death (related), intestinal hemorrhage (related). Atezolizumab arm: hematophagic histiocytosis, lower respiratory tract infection. Atezolizumab + bevacizumab arm: intracranial hemorrhage (related), hemorrhage, pneumonia. Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo.
15 All-Cause AEs > 5% difference between arms and at a 20% frequency in either arm Fatigue Diarrhea Nausea Palmar-plantar Mucosal inflammation Dysgeusia Decreased appetite Cough Stomatitis Headache Arthralgia Rash Epistaxis Pyrexia Pruritus Proteinuria 80% Atezolizumab + Bevacizumab All-Grade AEs Grade 3-5 AEs Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. Sunitinib All-Grade AEs Grade 3-5 AEs 60% 40% 20% 0 20% 40% 60% 80%
16 All-Cause AEs > 5% difference between arms and at a 20% frequency in either arm Fatigue Diarrhea Nausea Palmar-plantar Hypertension Mucosal inflammation Constipation Dysgeusia Decreased appetite Stomatitis Headache Vomiting Rash Pyrexia 80% All-Grade AEs Grade 3-5 AEs Clinical cut-off, Oct 17, Median duration of follow-up, 20.7 mo. Atezolizumab Sunitinib All-Grade AEs Grade 3-5 AEs 60% 40% 20% 0 20% 40% 60% 80%
17 Conclusions Atezolizumab + bevacizumab resulted in encouraging efficacy vs sunitinib in the PD-L1+ subgroup of first-line mrcc patients IRF-assessed PFS HR = 0.64 (95% CI, 0.38, 1.08) Median PFS = 14.7 mo with atezolizumab + bevacizumab and 7.8 mo with sunitinib The clinical benefit of atezolizumab + bevacizumab vs sunitinib will be evaluated in the ongoing Phase III study (IMmotion151; NCT ) The data corroborate the clinical activity of atezolizumab monotherapy in first-line mrcc 1 ITT: ORR 25%, CR 11%; PD-L1+: ORR 28%, CR 15% (IRF assessment) Safety in the atezolizumab arm and the atezolizumab + bevacizumab arm was consistent with previous data of each drug alone After first-line treatment, 78% of sunitinib and 60% of atezolizumab patients who progressed subsequently received atezolizumab + bevacizumab. Analysis of crossover treatment is currently ongoing 1. Herbst Nature 2014.
18 Acknowledgments The patients and their families The investigators and clinical study sites Christina Schiff, MD, medical monitor, Jiaheng Qiu, PhD, study statistician and Alpa Thobhani, MSc, clinical development scientist This study is sponsored by F. Hoffmann-La Roche, Ltd Medical writing for this presentation was provided by Jessica Bessler, PhD, of Health Interactions and funded by F. Hoffmann-La Roche, Ltd.
A Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationBlocking VEGF in addition to checkpoint inhibition in RCC
Blocking VEGF in addition to checkpoint inhibition in RCC Priti S. Hegde, PhD Director, CI Franchise Lead, Biomarkers Genentech/Roche 15 th IKCS Miami, FL The Tumor Immunity Continuum Known factors that
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationMedia Release. Basel, 18 February 2017
Media Release Basel, 18 February 2017 Phase II study supports potential for Roche s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationAmreen Husain, 10 Eric P. Winer, 11 Sylvia Adams, 12 Peter Schmid 13
IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naive, locally
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationClinical Activity and Safety of Anti-PD-1 (BMS , MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer
Clinical Activity and Safety of Anti-PD-1 (BMS-936558, MDX-1106) in Patients with Advanced Non-Small-Cell Lung Cancer J.R. Brahmer, 1 L. Horn, 2 S.J. Antonia, 3 D. Spigel, 4 L. Gandhi, 5 L.V. Sequist,
More informationLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic, 1 MR Migden, 2 AE Oro, 3 L Dirix, 4 K Lewis,
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationDISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationPembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study
Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 2 KEYNOTE-087 Study Craig H. Moskowitz, 1 Pier Luigi Zinzani, 2 Michelle A. Fanale, 3 Philippe Armand, 4 Nathalie Johnson, 5 John
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationThe High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC
The High-Dose Aldesleukin (IL-2) Select Trial in Patients with Metastatic RCC D McDermott, M Ghebremichael, S Signoretti, K Margolin, J Clark, J Sosman, J Dutcher, T Logan, R Figlin and M Atkins on behalf
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationPresenter Disclosure Information
Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444 Lawrence Fong, John Powderly II, Jason
More informationE2804 The BeST Trial
E2804 The BeST Trial A randomized Phase II Study of VEGF, RAF Kinase and MTOR Combination Targeted Therapy with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma Investigators Keith
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationIMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC
IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationBrain mets under I.O.
Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationLOTUS (NCT ) randomized phase II trial
Overall survival update of the double-blind placebocontrolled randomized phase 2 LOTUS trial of firstline ipatasertib + paclitaxel for locally advanced/metastatic triple-negative breast cancer Rebecca
More informationRenal Cell Cancer: Present and Future. Bernard Escudier, Gustave Roussy
Renal Cell Cancer: Present and Future Bernard Escudier, Gustave Roussy [HKIOF May 2017] Sponsored by Bristol- Myers Squibb OPDIVO Hong Kong prescribing information is available upon request Disclosures
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationPresented at the 58 th American Society of Hematology Annual Meeting and Exposition, December 5, 2016, San Diego, CA
1070 Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of
More informationBiomarcadores em Imuno-Oncologia André P. Fay, MD, PhD
Biomarcadores em Imuno-Oncologia André P. Fay, MD, PhD Professor of Medicine - PUCRS School of Medicine Chief, Medical Oncology Depatrment at HSL/PUCRS Visiting Scientist at Dana-Farber/Harvard Medical
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationIMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
More informationImmunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology
Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology 2013: Breakthrough of the Year December 20, 2013 Why immunotherapy? Immune
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationIncorporating biologics in the management of older patients with metastatic colorectal cancer
Incorporating biologics in the management of older patients with metastatic colorectal cancer D Papamichael MB BS MD FRCP Cyprus Oncology Centre GSK Satellite Symposium SIOG APAC Singapore 12-13 July 2014
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNeratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial
Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial Anishka D Souza 1, Lynda D. Roman 1, Cristina Saura 2, Irene Braña 2, Geoffrey I. Shapiro
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmunotherapy in GU Cancers. Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore
Immunotherapy in GU Cancers Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore 1 Disclosures Speaker Bureau: Pfizer, J&J, Sanofi, Novartis, MSD Advisory Board/ Consultant: GSK,
More informationesmo.org ESMO IMMUNO-ONCOLOGY CONGRESS 2017
ESMO IMMUNO-ONCOLOGY CONGRESS 2017 Primary PFS and safety analyses of a randomised Phase III study of carboplatin + paclitaxel +/ bevacizumab, with or without atezolizumab in 1L non-squamous metastatic
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationRepurposed RET Inhibitors : poor RET coverage in humans MKI Approved Dose Toxicities
LOXO-292, a Potent, Highly Selective RET Inhibitor, in Multi-Kinase Inhibitor-Resistant RET Fusion-Positive Lung Cancer Patients with and without Brain Metastases Vamsidhar Velcheti 1, Todd Bauer 2, Vivek
More informationIMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations
IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations Tony Mok, 1 Mark A. Socinski, 2 Martin Reck, 3 Robert Jotte, 4,5 Darren Wan-Teck Lim, 6 Federico Cappuzzo, 7 Francisco
More informationTOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD
Abstract #1527O TOP-LINE DATA FROM THE RANDOMIZED PHASE 2 IMPULSE STUDY IN SMALL-CELL LUNG CANCER (SCLC): IMMUNOTHERAPEUTIC MAINTENANCE TREATMENT WITH LEFITOLIMOD M. Thomas, S. Ponce-Aix, A. Navarro Mendivil,
More informationRenal Cell (RCC) and Bladder Carcinoma (TCC)
Renal Cell (RCC) and Bladder Carcinoma (TCC) Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Disclosures Compensated lectures: BMS, Ipsen,
More informationAdvances in the Treatment of Renal Cell Carcinoma
Advances in the Treatment of Renal Cell Carcinoma Developed in collaboration Learning Objectives Upon completion, participants should be able to: Identify patients with metastatic renal cell carcinoma
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationCondition or disease Intervention/treatment Phase. Drug: Gemcitabine. Drug: Oxaliplatin. Drug: Leucovorin. Drug: Fluorouracil. Drug: Atezolizumab
Find Studies About Studies Submit Studies Resources About Site A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More information